Novel Drug Modalities DMPK Enabling Platforms
WuXi AppTec DMPK has extensive experience and established pharmacokinetics evaluation systems for ADC, PDC, Oligo, Peptide, mRNA, Covalent Drugs, Proteolysis Targeting Chimera (PROTAC*) pharmacokinetic studies based on the in vivo and in vitro pharmacokinetic studies platform – to help drug developers quickly advance their drug development projects.
-
Overview
-
Novel Drug Modalities
-
FAQs
-
Related Resources
-
Related Services
Novel Drug Modalities
Overview
Our dedicated R&D team has summarized pharmacokinetic research strategies and established comprehensive evaluation solution from in vitro to in vivo for different novel drug modalities. The team consists of experts in different fields covering in vitro and in vivo ADME, metabolite identification, QWBA and radiolabeled mass balance, and bioanalysis.
We have collaborated with pharmaceutical and biotech companies focusing on new drug modalities. We have successfully supported thousands of projects and conducted extensive testing on tens of thousands of drug molecules, including peptides, antibodies, oligonucleotides, PROTACs, ADCs, PDCs, mRNA, Covalent Drugs, and etc.
Learn More
Novel Drug Modalities
-
PROTAC DMPK Services
Based on the pharmacokinetics evaluation systems for PROTAC molecules, WuXi AppTec DMPK has supported the screening of tens of thousands of PROTAC molecules and the IND applications of dozens of PROTAC molecules. In this process, we have formed a unique methodology for PROTAC pharmacokinetic studies - aimed at helping drug developers rapidly advance their PROTAC drug development projects.
-
ADC (Antibody-Drug Conjugate) DMPK Services
Based on the ADC integrated platform, WuXi AppTec DMPK has supported more than 200 ADCs for screening and more than 20 ADCs for IND filing. Throughout this process, we have accumulated extensive experience and can propose a specific DMPK strategy for each ADC project, which can effectively shorten the ADC development cycle.
-
Oligonucleotide Drugs DMPK Services
We have helped more than 70 global clients successfully screen and evaluate oligonucleotide pipelines, and have enabled dozens of oligonucleotide molecules’ IND applications, including ASO, siRNA, miRNA, and more. We not only have extensive experience in studying oligonucleotides but also have developed a specific methodology for the pharmacokinetic study of oligonucleotide drugs.
-
Peptide-Drug Conjugate (PDC) DMPK Services
Based on the characteristics of PDCs, the development strategy and assay condition of PDCs are customized according to our experience. WuXi AppTec DMPK has successfully supported more than 20 clients on PDC projects, including some IND-enabling studies.
-
Peptide Drugs DMPK Services
Based on the peptide integrated platform, WuXi AppTec DMPK has supported more than 140 global clients on peptide projects, including the screening of tens of thousands of peptide molecules and the IND applications of dozens of peptide molecules.
-
mRNA-Based Vaccines and Therapeutics Drugs DMPK Services
To facilitate the research and development of mRNA-based vaccines and therapeutics, WuXi AppTec DMPK has established an integrated bioanalytical platform. This platform includes qPCR, branched DNA (bDNA), ligand binding assays (LBA), liquid chromatography-mass spectrometry (LC-MS), and flow cytometry, enabling quantitative and semi-quantitative analysis of mRNA.
-
Covalent Drugs DMPK Services
The mechanism of covalent drugs is different from that of conventional small molecule drugs, which may bring corresponding challenges to the ADME studies, such as distribution and elimination studies. WuXi AppTec DMPK has established ADME platforms specially for covalent drugs. Up to now, WuXi AppTec DMPK has successfully supported nearly 100 covalent drug projects for clients and has successfully pushed many covalent drugs into clinical trials.
FAQs
-
Why are novel drug modalities important?
1. Addressing Unmet Medical Needs
Novel Drug Modalities (like oligonucleotides, peptides, and ADCs) target previously “undruggable” targets - opening doors to treat rare diseases, certain cancers, and genetic disorders that small molecules couldn’t address effectively.
2. Precision Medicine Potential
These therapies offer unprecedented target specificity. For example, ADCs deliver cytotoxic payloads directly to tumor cells; Oligonucleotides can precisely modulate RNA expression. This reduces off-target effects compared to traditional drugs.
3. Accelerated Development Timelines
Many Novel Drug Modalities benefit from streamlined regulatory pathways (e.g., orphan drug designations), biomarker-driven development, and smaller clinical trials for diseases.
4. Future-Proofing Drug Pipelines
Novel Therapeutic modalities represent the cornerstone of next-generation therapeutics and long-term commercial viability.
Related Resources
-
Magnetic Solid-phase Extraction for LC-MS/MS Analysis of GalNAc-Conjugated Oligonucleotides in Plasma and Urine
PostersJun 18, 2026Learn More
-
A Robust LC-MS/MS Method for Determination of Schiff-base Forming Reversible Covalent Inhibitors in Whole Blood
PostersJun 18, 2026Learn More -
How to Increase Oral Bioavailability of PROTAC Drugs: 7 Key Strategies to Overcome Druggability Challenges
ArticlesJun 18, 2026Learn More -
A Robust LC-MS/MS Method for Quantitative Bioanalysis of siRNA Antisense Strand in Mouse Serum and Liver
PostersJun 12, 2026Learn More -
Rapid Profiling and Characterization of Payload-Related Catabolites Derived from ADCs in In Vitro Model by HRMS
PostersJun 05, 2026Learn More -
DMPK Strategies for Proteolysis-Targeting Chimeras: Addressing ADME and PK Challenges
WebinarsJun 05, 2026Learn More -
Comprehensive Characterization of ADC Biotransformation in In Vitro Plasma Using UPLC-HRMS
PostersJun 05, 2026Learn More -
An Integrated Mass Spectrometry-Based Platform for the Multiplexed Quantification of Antibody-Oligonucleotide Conjugates (AOCs)
PostersJun 05, 2026Learn More -
FDA-Approved Drugs in 2025: Overview of Human Pharmacokinetics (PK) and Drug-drug Interactions (DDI)
ArticlesJun 05, 2026Learn More -
Investigation Strategies of the ADC Payload with Thiol Group in In Vivo Samples
PostersMay 30, 2026Learn More -
Optimizing Oral Formulation for Peptides and Novel Molecules: Breaking the Delivery Dilemma
ArticlesMay 28, 2026Learn More -
TidesID - Fast & Accurate Metabolite Identification for Peptides & Oligonucleotides 丨DMPK Frontiers
VideosMay 28, 2026Learn More -
Development of Auto-immunocapture based Integrated Mass Spectrometry Platform for Qualitative and Quantitative Study of Fusion Protein Drug
PostersMay 24, 2026Learn More -
Determination of DS-8201 in Rat Plasma Using mSPE Magnetic Beads Method in Couple with Liquid Chromatography-Tandem Mass Spectrometry
PostersMay 24, 2026Learn More -
Bioanalysis Publication: An Ultra-Sensitive UPLC-MS Method for ADC Payload Analysis Developed by WuXi AppTec DMPK
ArticlesMay 14, 2026Learn More -
DMPK Strategies for Advancing Preclinical Development of AOC Therapeutics
WebinarsMay 14, 2026Learn More -
Viscosity Reduction Formulation Strategies for High-Concentration Injectables
BlogsMay 08, 2026Learn More -
Why Surfactants Are Critical in Biologic Injectables and How to Choose Them
BlogsApr 29, 2026Learn More -
ADC DAR Analysis: Qualitative & Quantitative Dual-Strategy for In Vivo Profiling丨DMPK Frontiers
VideosApr 23, 2026Learn More -
A Novel RT-qPCR Methodology for Quantitative Bioanalysis of Total and Conjugated siRNA in Antibody-Oligonucleotide Conjugates (AOCs)
PostersApr 17, 2026Learn More -
Development and Validation of an Ultra-Sensitive UPLC-MS/MS Method for Quantification of Monomethyl Auristatin E in Cynomolgus Monkey Plasma: Application to Pharmacokinetic Study
PublicationsMar 26, 2026Learn More -
Tackling Oligonucleotide Analysis Challenges with Optimized Sample Preparation for LC–MS/MS
ArticlesMar 26, 2026Learn More -
A High-Sensitivity Stem-Loop RT-qPCR Method for RISC-Loaded siRNA Quantitation
PostersMar 26, 2026Learn More -
In Vitro Metabolism Studies of 5 acrylamide Covalent Drugs: Comparison with Metabolism and Disposition in Human
PublicationsMar 19, 2026Learn More -
Establishment of a Quantitative Analytical Method for Albumin-Drug Conjugates in Rat Plasma Using Ultra-high Performance Liquid Chromatography-Tandem Mass Spectrometry
PostersMar 17, 2026Learn More -
DMD Publication: A New In Vitro System for Predicting Covalent Drug Metabolism Established by WuXi AppTec DMPK
BlogsMar 11, 2026Learn More -
Unlocking Peptide Receptor Radionuclide Therapies (PRRTs) and Diagnostic PRCs: What, Why, and Their Metabolic Studies
ArticlesMar 06, 2026Learn More -
Addressing pH-Dependent Lactone–Carboxylate Interconversion to Resolve Quantitation Bias in the Bioanalysis of Exatecan-Based ADCs
PostersMar 02, 2026Learn More -
Deciphering Nucleoside and Analogs: Mechanisms, Landscape, and Their Phosphates Analysis based on LC-MS/MS
ArticlesFeb 27, 2026Learn More -
Research on the Lymphatic Transport: Enhancing Drug Delivery and Absorption via In Vivo Models
ArticlesFeb 16, 2026Learn More -
Neonatal Fc Receptor (FcRn): Advances in Autoimmune Therapeutics and Analytical Strategies
ArticlesFeb 10, 2026Learn More -
A Review on ADC Linkers: Cleavable and Non-Cleavable Linker Design and Stability Evaluation
ArticlesJan 30, 2026Learn More -
Elimination of Interferences from ADC in Detection of Free Payloads in Biological Matrix with LC-MS/MS
PostersJan 24, 2026Learn More -
Development of an Automated Integrated Mass Spectrometry Platform for Qualitative and Quantitative Study of Peptide-Fc Fusion Protein
PostersJan 24, 2026Learn More -
mRNA Therapeutics Quantification: RT-qPCR vs. bDNA Analytical Methods
ArticlesJan 23, 2026Learn More -
Efficient Synthesis of Multi-14C-Labeled Fatty Acid-Modified Peptides
PostersJan 18, 2026Learn More -
Evaluation of Time-Dependent Inhibition (TDI) of CYP3A4 by Peptide Therapeutics:A Comparison of Human Hepatocyte and Human Liver Microsome Assays
PostersJan 18, 2026Learn More -
Liposome Drug Delivery: Classification, Composition, and Formulation Considerations
ArticlesJan 16, 2026Learn More -
Software-aided Detection and Structural Characterization of Cyclic Peptide Metabolites in Biological Matrix by High-resolution Mass Spectrometry
PublicationsJan 09, 2026Learn More -
GLP-1 Peptide Drug Radiolabeling and ADME Study Strategies
ArticlesDec 24, 2025Learn More -
Review on the Bioanalysis of Non-Virus-Based Eene Therapeutics
PublicationsDec 19, 2025Learn More -
Approved Antibody Fragments and DMPK Strategies: Fab, scFv, and VHH
ArticlesDec 11, 2025Learn More -
What Are Antibody–Oligonucleotide Conjugates (AOCs) and Their Structural Characteristics
ArticlesNov 28, 2025Learn More -
What Are Antibody–Peptide Conjugates (APCs) Drugs and Their Pharmacokinetic Properties
ArticlesNov 21, 2025Learn More -
Establishment of a High-Throughput Screening and Characterization Platform for Covalent Inhibitor Drugs
PostersNov 21, 2025Learn More -
Integrated Bioanalytical Platform and DMPK Strategies for Antibody-Drug Conjugates
WebinarsNov 13, 2025Learn More -
Sensitive LC-MS/MS Method for Cationic Ligand-Conjugated siRNA Therapeutics
PostersNov 08, 2025Learn More -
Overcoming Challenges in Oligonucleotide Metabolism with Innovative Solutions -WuXi AppTec DMPK TechTalk
VideosNov 07, 2025Learn More -
In Vitro Platform for Assessing ADC Stability and Payload Release
PostersOct 31, 2025Learn More -
Decoding Peptide ADME Challenges: Integrated Radiolabeled Synthesis & ADME Platform - DMPK Frontiers
VideosOct 24, 2025Learn More
Related Services
Stay Connected
Keep up with the latest news and insights.
